CAMBRIDGE, Mass., Feb. 23, 2023 (GLOBE NEWSWIRE) — Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology corporate pioneering the advance of a brand new magnificence of programmable epigenetic mRNA medications, these days introduced that it has entered right into a securities acquire settlement with traders in a registered direct providing of 6,920,415 stocks of not unusual inventory (the “Stocks”) at a purchase order value of $5.78 in step with proportion, leading to gross proceeds of roughly $40 million. The providing integrated participation by means of new and current traders.
The providing is anticipated to near on February 27, 2023, matter to normal remaining stipulations. Because the providing used to be made with out an underwriter or a placement agent, Omega might not be paying any underwriting reductions or placement agent charges in reference to the providing.
The Stocks have been introduced pursuant to a shelf registration commentary on Shape S-3 (Report No. 333-268254) that used to be in the past filed with the U.S. Securities and Alternate Fee (the “SEC”) and declared efficient by means of the SEC on November 18, 2022. A last prospectus complement, which incorporates additional info on the subject of the providing, will probably be filed with the SEC and will probably be to be had at the SEC’s website online at www.sec.gov.
This press free up does now not represent an be offering to promote or the solicitation of an be offering to shop for the Stocks, nor shall there be any sale of the Stocks in any state or different jurisdiction wherein such be offering, solicitation or sale can be illegal previous to the registration or qualification beneath the securities regulations of such a state or different jurisdiction.
About Omega Therapeutics
Omega Therapeutics, based by means of Flagship Pioneering, is a clinical-stage biotechnology corporate pioneering the advance of a brand new magnificence of programmable epigenetic mRNA medications. The Corporate’s OMEGA platform harnesses the facility of epigenetics, the mechanism that controls gene expression and each and every side of an organism’s lifestyles from mobile genesis, enlargement, and differentiation to mobile demise. The use of a collection of applied sciences, paired with Omega’s technique of systematic, rational, and integrative drug design, the OMEGA platform permits keep an eye on of elementary epigenetic processes to proper the basis explanation for illness by means of returning aberrant gene expression to a regular vary with out changing local nucleic acid sequences. Omega’s modular and programmable mRNA medications, Omega Epigenomic Controllers™, goal explicit epigenomic loci inside of insulated genomic domain names, EpiZips, from among hundreds of distinctive, mapped, and validated genome-wide DNA-sequences, with prime specificity to durably track unmarried or a couple of genes to regard and treatment sicknesses via remarkable precision epigenomic keep an eye on. Omega’s pipeline of product applicants span a variety of illness spaces, together with oncology, regenerative medication, multigenic sicknesses together with immunology, and choose monogenic sicknesses.
Ahead-Having a look Statements
This press free up incorporates forward-looking statements inside the that means of the Personal Securities Litigation Reform Act of 1995. All statements contained on this press free up that don’t relate to issues of historic truth must be regarded as forward-looking statements, together with with out limitation statements in regards to the of completion of the proposed providing, and expected proceeds of the proposed providing. Those statements are neither guarantees nor promises, however contain recognized and unknown dangers, uncertainties and different vital elements that can motive our precise effects, efficiency or achievements to be materially other from any long run effects, efficiency or achievements expressed or implied by means of the forward-looking statements, together with the hazards mentioned beneath the caption “Possibility Components” in our most up-to-date Quarterly Document on Shape 10-Q and our Annual Document on Shape 10-Okay for the yr ended December 31, 2021, and our different filings with the SEC, may motive precise effects to fluctuate materially from the ones indicated by means of the forward-looking statements made on this press free up. One of these forward-looking statements constitute control’s estimates as of the date of this press free up. Whilst we would possibly elect to replace such forward-looking statements someday at some point, we disclaim any legal responsibility to take action, even though next occasions motive our perspectives to modify.
CONTACT: CONTACT Eva Stroynowski Omega Therapeutics 617.949.4370 [email protected]